Evidence map›Paper›PMID 35077390›Full record

ArticleAging2022

Integrative bioinformatics and experimental analysis revealed TEAD as novel prognostic target for hepatocellular carcinoma and its roles in ferroptosis regulation.

Xinxin Ren, Xiang Wang, Yuanliang Yan, Xi Chen, Yuan Cai, Qiuju Liang, Bi Peng, Zhijie Xu, Qingchun He, Fanhua Kang and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. [Research progress on ferroptosis regulation in tumor immunity of hepatocellular carcinoma].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Xinxin RenCenter for Molecular Medicine, Xiangya Hospital, Key Laboratory of Molecular Radiation Oncology of Hunan Province, Central South University, Changsha 410008, Hunan, China.
Xiang WangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Yuanliang YanDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Xi ChenDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Yuan CaiDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Qiuju LiangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Bi PengDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Zhijie XuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Qingchun HeDepartment of Emergency, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Fanhua KangDepartment of Pathology, Xiangya Changde Hospital, Changde 415000, Hunan, China.
Jianbo LiDepartment of Pathology, Xiangya Changde Hospital, Changde 415000, Hunan, China.
Wenqin ZhangDepartment of Pathology, Xiangya Changde Hospital, Changde 415000, Hunan, China.
Qianhui HongDepartment of Pathology, Xiangya Changde Hospital, Changde 415000, Hunan, China.
Jinwu PengDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Muzhang XiaoDepartment of Burn and Plastic Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Central South University · CNThe First People's Hospital of Changde · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTranscriptional enhanced associate domain (TEAD) family consists of four members TEAD1/2/3/4 that regulate cell growth, stem cell functions and organ development. As the downstream of Hippo signaling pathway, TEAD family is involved in the progression of several cancers. However, the precise biology functions of TEAD family in hepatocellular carcinoma (HCC) have not been reported yet.

methodsWe apply bioinformatics analysis based on databases including UALCAN, Oncomine, GEPIA, Kaplan-Meier plotter, WebGestalt, cBioPortal, TIMER2.0, and

resultsThe results indicated that TEAD2/4 were significantly upregulated in HCC compared with normal tissues. Downregulated of TEAD2 could promote the death of HCC cells through inducing ferroptosis by iron accumulation and subsequent oxidative damage. According to the Kaplan-Meier plotter database, we found that the high expression of TEAD2 was significantly associated with poor disease-specific survival, overall survival, progression-free survival and relapse-free survival. In aspect of cancer immunity, Tumor Immune Estimation Resource algorithm showed that the expression of TEAD family members was obviously related to multiple of infiltrating immune cells including macrophages, neutrophils, dendritic cells, B cells, CD8+ T cells and CD4+ T cells. Finally, we conducted the functional enrichment analysis including protein-protein interaction network, gene ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway based on the TEAD family-associated coexpression genes.

conclusionThe study provided deep insight information of TEAD family in the diagnostic and prognostic evaluation of HCC patients.

Indexed as

Carcinoma, HepatocellularFerroptosisLiver NeoplasmsBiomarkers, TumorComputational BiologyHumansPrognosisBiomarkers, Tumorferroptosishepatocellular carcinomahippo pathwayimmune infiltrationTEAD family

Identifiers

PMID35077390
PMCPMC8833120
OpenAlexW4207084806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.